Tirzepatide vs Semaglutide: The Head-to-Head Results
For years this was argued using separate trials with different populations - which proves nothing. Then SURMOUNT-5 put the two drugs against each other directly. Here is what it found, and the three situations where semaglutide is still the better answer.
Last updated: August 3, 2026
Quick Answer
Tirzepatide won decisively. In SURMOUNT-5 - the head-to-head trial published in the New England Journal of Medicine - tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide in the primary analysis. In absolute terms that was an average of 22.8 kg with tirzepatide versus 15.0 kg with semaglutide.
Tirzepatide participants were also more likely to hit every weight loss threshold - at least 10%, 15%, and 20% - and achieved greater waist circumference reduction. The trial concluded that among adults with obesity but without diabetes, tirzepatide was superior to semaglutide.
That does not make semaglutide the wrong choice for everyone. Cost, tolerability, and semaglutide's broader set of approved indications all still matter - and are covered below.
SURMOUNT-5: The Results
SURMOUNT-5 enrolled adults with obesity but without type 2 diabetes and randomised them to tirzepatide or semaglutide. Both groups were treated to their maximum tolerated doses, so this was a genuine test of the drugs at their best.
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Mean weight loss (primary analysis) | 20.2% | 13.7% |
| Absolute weight lost | 22.8 kg (~50 lbs) | 15.0 kg (~33 lbs) |
| Reaching 10%+ loss | More likely | Less likely |
| Reaching 15%+ loss | More likely | Less likely |
| Reaching 20%+ loss | More likely | Less likely |
| Waist circumference | Greater reduction | Smaller reduction |
The gap is roughly 6.5 percentage points - which for a 250 lb starting weight works out to about 16 additional pounds. That is not a rounding error.
Longer-term data has reported mean weight reductions of up to 22.9% after nearly 3.5 years, indicating the effect is not confined to the first year.
The threshold data is arguably more useful than the average. Averages hide variation. What matters when you are choosing is your probability of hitting a meaningful result - and tirzepatide made participants more likely to reach every threshold measured. If your goal requires losing 20% or more, that difference in odds is the number to weigh.
Why a Head-to-Head Trial Matters
Before SURMOUNT-5, every comparison you read was cross-trial - taking the result from one drug's trial and setting it next to another drug's trial. That approach is genuinely unreliable, because the trials differ in:
- Population - starting BMI, age distribution, comorbidities, and sex balance all vary
- Duration - a 72-week trial is not comparable to a 68-week one
- Lifestyle intervention - the diet and activity support given alongside the drug differs
- Analysis method - treatment policy versus efficacy estimands produce different numbers from identical data
A randomised head-to-head trial eliminates all of that. Same population, same protocol, same measurement, same time period - the only variable is the drug. That is why SURMOUNT-5 carries far more weight than years of side-by-side comparison tables, including our own earlier ones.
It is also worth noting what the trial did not cover: participants had obesity without diabetes. In people with type 2 diabetes, both drugs produce less weight loss, and the relative gap has been studied separately.
Why Tirzepatide Wins on Weight
The mechanism explains the result cleanly.
| Drug | Receptors Targeted | Max Dose |
|---|---|---|
| Semaglutide | GLP-1 only | 2.4 mg weekly (Wegovy) |
| Tirzepatide | GLP-1 + GIP dual agonist | 15 mg weekly |
Tirzepatide adds GIP receptor agonism on top of GLP-1. GIP amplifies the metabolic effects of GLP-1 and appears to improve gastrointestinal tolerability, which in turn allows patients to reach higher effective exposure. Two mechanisms working together outperform one.
This is also why the next generation of drugs keeps adding targets - retatrutide adds glucagon for a triple agonist, and amycretin pairs GLP-1 with amylin. See our guides to retatrutide and amycretin.
One thing SURMOUNT-5 did not test: the higher-dose Wegovy HD (semaglutide 7.2 mg), which reaches roughly 20.7% in its own trials. The comparison used semaglutide 2.4 mg. Whether high-dose semaglutide would close the gap against tirzepatide has not been tested head-to-head - so treat any claim that it does, or does not, as speculation. See our Wegovy HD guide.
Three Reasons to Still Choose Semaglutide
"Superior for weight loss" is not the same as "better for you." Three genuine arguments remain.
1. Far Broader Approved Indications
Semaglutide carries FDA approvals for cardiovascular risk reduction (Wegovy), MASH with liver fibrosis (Wegovy), and reducing kidney disease progression in type 2 diabetes with CKD (Ozempic) - in addition to weight management and diabetes. Tirzepatide covers weight management, sleep apnea, and diabetes. If you have heart, liver, or kidney disease, semaglutide may be the clinically indicated choice regardless of the weight numbers, and the indication is often what unlocks coverage. See our guide to every FDA-approved indication.
2. Cost and Access
Semaglutide self-pay pricing starts lower - Wegovy from $149/month at starting doses - and compounded semaglutide programmes typically run less than compounded tirzepatide. A drug you can afford for three years beats a better drug you stop after eight months, particularly since weight regain after discontinuation is well documented.
3. Individual Tolerability
Trial averages describe populations, not people. Some patients tolerate one molecule considerably better than the other, and there is no way to predict which in advance. If you have already tried tirzepatide and could not tolerate it, semaglutide is a legitimate alternative rather than a consolation prize - and the reverse is equally true.
Side Effects Compared
Both drugs share the GLP-1 class profile: nausea, vomiting, diarrhoea, constipation, and reflux, concentrated during dose escalation. Both carry the boxed warning for thyroid C-cell tumours and the same warnings on pancreatitis, gallbladder disease, and hypoglycaemia when combined with insulin or sulfonylureas.
The GIP component in tirzepatide is thought to improve gastrointestinal tolerability relative to what an equivalent GLP-1 exposure alone would produce - which is part of why higher effective doses are achievable. In practice, both are broadly comparable in how well patients tolerate them, and individual variation is larger than the difference between drugs.
Practical management guides: managing GLP-1 nausea, managing constipation, and hair shedding.
A consequence of winning on weight loss: more weight lost means more total tissue lost, and without deliberate intervention a meaningful share of that is lean mass. At tirzepatide-level results, protein intake and resistance training are not optional. See our muscle loss prevention guide.
Cost Compared
| Option | Monthly Self-Pay |
|---|---|
| Zepbound vials (tirzepatide) | $299-$449 by dose |
| Wegovy (semaglutide 2.4 mg) | $149-$349 by dose |
| Wegovy HD (7.2 mg) | $399 |
| Compounded semaglutide | From $249 all-inclusive |
| Medicare GLP-1 Bridge | $50 copay (eligible beneficiaries) |
The gap has narrowed considerably. At $449 for tirzepatide versus $349 for standard-dose semaglutide, the extra 6.5 percentage points of weight loss costs about $100 a month - which many people will judge worth it. Full breakdowns in our Zepbound cost guide and cost comparison.
How to Decide
| Your Situation | Likely Better Choice |
|---|---|
| Maximum weight loss is the priority, cost is manageable | Tirzepatide |
| Established cardiovascular disease | Semaglutide (Wegovy CV indication) |
| Diagnosed MASH with fibrosis | Semaglutide (Wegovy MASH indication) |
| Type 2 diabetes with chronic kidney disease | Semaglutide (Ozempic CKD indication) |
| Moderate-to-severe sleep apnea with obesity | Tirzepatide (Zepbound OSA indication) |
| Paying cash and cost-sensitive long term | Semaglutide |
| Already failed or could not tolerate one of them | Try the other |
Affordable Semaglutide from $249/month
If cost is what decides it for you, Coreage Rx provides physician-supervised compounded semaglutide at one flat all-inclusive rate - consultation, medication, shipping, and ongoing dose management, with no insurance required and no membership fee.
Frequently Asked Questions
Which is better, tirzepatide or semaglutide?
For weight loss, tirzepatide - and it is settled by direct evidence rather than inference. In the SURMOUNT-5 head-to-head trial published in NEJM, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide, or 22.8 kg versus 15.0 kg in absolute terms, and participants were more likely to reach every threshold measured. Semaglutide remains preferable in specific situations involving cardiovascular, liver, or kidney indications, or when cost is decisive.
What did the SURMOUNT-5 trial show?
SURMOUNT-5 randomised adults with obesity but without type 2 diabetes to tirzepatide or semaglutide at maximum tolerated doses. Tirzepatide produced 20.2% mean weight loss versus 13.7%, greater waist circumference reduction, and a higher likelihood of reaching 10%, 15%, and 20% weight loss thresholds. The trial concluded tirzepatide was superior to semaglutide in this population.
Why does a head-to-head trial matter more than comparing separate studies?
Because cross-trial comparisons are unreliable. Separate trials differ in population, starting BMI, duration, the lifestyle support provided, and the statistical method used to report results - any of which can shift a number by several percentage points. A randomised head-to-head trial holds all of that constant so the drug is the only variable.
Why is tirzepatide more effective?
Tirzepatide is a dual agonist activating both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone. GIP amplifies the metabolic effects of GLP-1 and appears to improve gastrointestinal tolerability, which allows higher effective exposure. This is the same logic driving the next generation - retatrutide adds glucagon as a triple agonist, and amycretin pairs GLP-1 with amylin.
Would Wegovy HD have beaten tirzepatide?
Unknown - SURMOUNT-5 compared tirzepatide against semaglutide 2.4 mg, not against the higher-dose Wegovy HD at 7.2 mg, which reaches roughly 20.7% in its own separate trials. No head-to-head trial has tested high-dose semaglutide against tirzepatide, so any claim about how that would turn out is speculation rather than evidence.
Are the side effects different between them?
Broadly similar. Both share the GLP-1 class profile - nausea, vomiting, diarrhoea, constipation, reflux - concentrated during dose escalation, and both carry the same boxed warning for thyroid C-cell tumours and warnings on pancreatitis and gallbladder disease. Individual variation between people is generally larger than the difference between the two drugs.
Should I switch from semaglutide to tirzepatide?
It is a reasonable conversation with your prescriber if you have plateaued short of your goal and can afford the difference - roughly $100 a month more at self-pay maintenance doses. But if semaglutide is working, is affordable, or is the indicated choice for a cardiovascular, liver, or kidney condition you have, switching purely on trial averages may not serve you. Never switch GLP-1s without prescriber management, as the titration schedules differ.
Does tirzepatide beat semaglutide in people with diabetes too?
SURMOUNT-5 specifically enrolled adults with obesity but without diabetes, so it does not answer that question. Both drugs produce less weight loss in people with type 2 diabetes than in those without, and the relative comparison in that population has been examined in separate research. If you have diabetes, that is a discussion for your prescriber rather than an extrapolation from this trial.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Tirzepatide and semaglutide are prescription medications that should only be used under the supervision of a qualified healthcare provider. Clinical trial figures represent group averages from a specific study population - adults with obesity without type 2 diabetes - and do not predict individual results. Never start, stop, or switch between GLP-1 medications without prescriber direction, as titration schedules differ. Always review full prescribing information for complete warnings and contraindications. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.